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BACKGROUND
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. 
Safety data are available for the subcutaneous form of the glucagon-like peptide-1 recep-
tor agonist semaglutide but are needed for oral semaglutide.
METHODS
We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven, 
randomized, double-blind, placebo-controlled trial involving patients at high cardiovas-
cular risk (age of ≥50 years with established cardiovascular or chronic kidney disease, or 
age of ≥60 years with cardiovascular risk factors only). The primary outcome in a time-
to-event analysis was the first occurrence of a major adverse cardiovascular event (death 
from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The 
trial was designed to rule out 80% excess cardiovascular risk as compared with placebo 
(noninferiority margin of 1.8 for the upper boundary of the 95% confidence interval for 
the hazard ratio for the primary outcome).
RESULTS
A total of 3183 patients were randomly assigned to receive oral semaglutide or placebo. The 
mean age of the patients was 66 years; 2695 patients (84.7%) were 50 years of age or older 
and had cardiovascular or chronic kidney disease. The median time in the trial was 15.9 
months. Major adverse cardiovascular events occurred in 61 of 1591 patients (3.8%) in the 
oral semaglutide group and 76 of 1592 (4.8%) in the placebo group (hazard ratio, 0.79; 95% 
confidence interval [CI], 0.57 to 1.11; P<0.001 for noninferiority). Results for components 
of the primary outcome were as follows: death from cardiovascular causes, 15 of 1591 
patients (0.9%) in the oral semaglutide group and 30 of 1592 (1.9%) in the placebo group 
(hazard ratio, 0.49; 95% CI, 0.27 to 0.92); nonfatal myocardial infarction, 37 of 1591 pa-
tients (2.3%) and 31 of 1592 (1.9%), respectively (hazard ratio, 1.18; 95% CI, 0.73 to 1.90); 
and nonfatal stroke, 12 of 1591 patients (0.8%) and 16 of 1592 (1.0%), respectively (hazard 
ratio, 0.74; 95% CI, 0.35 to 1.57). Death from any cause occurred in 23 of 1591 patients 
(1.4%) in the oral semaglutide group and 45 of 1592 (2.8%) in the placebo group (hazard 
ratio, 0.51; 95% CI, 0.31 to 0.84). Gastrointestinal adverse events leading to discontinu-
ation of oral semaglutide or placebo were more common with oral semaglutide.
CONCLUSIONS
In this trial involving patients with type 2 diabetes, the cardiovascular risk profile of oral 
semaglutide was not inferior to that of placebo. (Funded by Novo Nordisk; PIONEER 6 
ClinicalTrials.gov number, NCT02692716.)
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Cardiovascular disease is the pri-mary cause of death in patients with type 2 diabetes,1 and the ruling out of an excess 
cardiovascular risk is a regulatory requirement 
for new glucose-lowering therapies.2,3 Glucagon-
like peptide-1 (GLP-1) receptor agonists are well-
established glucose-lowering medications for the 
treatment of type 2 diabetes and are associated 
with reductions in body weight and a low risk of 
hypoglycemia.4-11 These agents have shown car-
diovascular safety (lixisenatide12 and exenatide13) 
and, in several cases, benefit (liraglutide,14 albi-
glutide,15 semaglutide,16 and, most recently, dula-
glutide17). For example, in the Trial to Evaluate 
Cardiovascular and Other Long-term Outcomes 
with Semaglutide in Subjects with Type 2 Diabe-
tes (SUSTAIN-6), patients who received a once-
weekly subcutaneous injection of semaglutide 
had a 26% lower risk of the primary cardiovas-
cular outcome than those who received placebo.16 
Recent diabetes and cardiology treatment guide-
lines recommend GLP-1 receptor agonists as a 
second-line treatment option for adults with 
type 2 diabetes.18,19
All currently approved GLP-1 receptor ago-
nists are administered subcutaneously. Oral sema-
glutide has been developed as a once-daily tab-
let, which may allay concerns about injections 
among some patients and clinicians20 and result 
in earlier initiation of GLP-1 receptor agonist 
therapy. As compared with once-weekly subcuta-
neous semaglutide, oral semaglutide has a dif-
ferent absorption profile.21,22 However, once the 
drug is absorbed, the pharmacokinetic properties 
and effects of semaglutide are similar, regard-
less of the route of administration.21,22 The present 
randomized, placebo-controlled, phase 3a trial, 
Peptide Innovation for Early Diabetes Treatment 
(PIONEER) 6, is a preapproval cardiovascular 
outcomes trial specifically designed to rule out 
an excess in cardiovascular risk with oral sema-
glutide among patients with type 2 diabetes.
Me thods
Trial Design and Oversight
Detailed methods for this trial, which was con-
ducted at 214 sites in 21 countries, have been 
published previously,23 and the protocol is avail-
able with the full text of this article at NEJM.org. 
The sponsor (Novo Nordisk) designed the trial 
and was responsible for the trial conduct, data 
collection, and data analysis. An independent 
data monitoring committee evaluated unblinded 
trial data.
All the authors had full access to the data, 
participated in drafting or critical revision of 
the manuscript, made the decision to submit the 
manuscript for publication, and vouch for the 
accuracy and completeness of the data and for 
the adherence of the trial to the protocol. The 
manuscript was drafted with support from a 
medical writer (funded by the sponsor), under 
the direction of the authors.
Patients
Patients were eligible to participate if they were 
50 years of age or older and had established 
cardiovascular disease or chronic kidney dis-
ease, or if they were 60 years of age or older and 
had cardiovascular risk factors only. Key exclu-
sion criteria were treatment with any GLP-1 re-
ceptor agonist, dipeptidyl peptidase 4 inhibitor, 
or pramlintide within 90 days before screening; 
New York Heart Association class 4 heart failure; 
planned coronary-artery, carotid-artery, or periph-
eral-artery revascularization; myocardial infarc-
tion, stroke, or hospitalization for unstable an-
gina or transient ischemic attack within 60 days 
before screening; long-term or intermittent hemo-
dialysis or peritoneal dialysis, or severe renal 
impairment (estimated glomerular filtration rate 
[GFR], <30 ml per minute per 1.73 m2 of body-
surface area); and proliferative retinopathy or 
maculopathy resulting in active treatment. The 
full eligibility criteria are provided in the Supple-
mentary Appendix, available at NEJM.org.
Procedures
Patients were randomly assigned (in a 1:1 ratio) 
to receive once-daily oral semaglutide (target 
dose, 14 mg) or placebo (Fig. S1 in the Supple-
mentary Appendix), both in addition to standard-
of-care treatment, in a double-blind fashion. 
Randomization was stratified according to evi-
dence of established cardiovascular disease or 
chronic kidney disease or the presence of cardio-
vascular risk factors only.
Patients were instructed to take oral semaglu-
tide or placebo in the morning, with up to 120 ml 
of water, in a fasting state, and at least 30 min-
utes before eating, drinking, or taking any other 
oral medication. A dose-escalation schedule was 
used to decrease gastrointestinal side effects.23 
Once the desired dose was reached, patients re-
mained at the maximum 14-mg daily dose unless 
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a reduction was warranted owing to problems 
with side effects. In such cases, investigators 
were encouraged to consider reescalating the 
dose once the symptoms had resolved or dimin-
ished. Investigators were encouraged to maintain 
and intensify patients’ existing glucose-lowering 
and cardiovascular medication, in accordance 
with local and international guidelines, in addi-
tion to semaglutide or placebo.
Follow-up appointments occurred every 6 to 
7 weeks in person or by telephone. A full sched-
ule of assessments is provided in the Supple-
mentary Appendix.
Outcomes
The primary outcome was the time from random-
ization to the first occurrence of a major adverse 
cardiovascular event, a composite of death from 
cardiovascular causes (including undetermined 
causes of death), nonfatal myocardial infarction, 
or nonfatal stroke. Secondary cardiovascular out-
comes included the time from randomization to 
the first occurrence of the following: an expanded 
composite outcome consisting of the primary 
outcome plus unstable angina resulting in hos-
pitalization or heart failure resulting in hospital-
ization; a composite of death from any cause, 
nonfatal myocardial infarction, or nonfatal stroke; 
and the individual components of these compos-
ite outcomes. Additional efficacy outcomes in-
cluded the change from baseline to the end of 
the treatment period in the glycated hemoglobin 
level, body weight, and lipid levels.
A select set of safety outcomes was investi-
gated, encompassing adverse events leading to 
discontinuation of semaglutide or placebo, serious 
adverse events, and adverse events of special in-
terest (including diabetic retinopathy assessed by 
scheduled eye examinations, and severe hypogly-
cemic episodes). Cardiovascular and other selected 
events were adjudicated by an independent, exter-
nal event-adjudication committee whose members 
were unaware of the trial-group assignments.
Statistical Analysis
The statistical methods have been reported pre-
viously,23 and further information is provided in 
the Supplementary Appendix and below. Our 
trial was an event-driven trial designed to rule 
out an 80% excess in cardiovascular risk with 
oral semaglutide by assessment of noninferiority 
to placebo for the primary outcome (noninferior-
ity margin of 1.8 for the upper boundary of the 
95% confidence interval for the hazard ratio). 
The trial continued until accrual of at least 122 
events, with no predefined minimum duration.
All analyses involved the full analysis set, 
which included all randomly assigned patients. 
The primary outcome encompassed events oc-
curring between randomization and the final 
follow-up visit (aligned at 5 weeks after the last 
trial-wide assigned dose, except for patients who 
withdrew from the trial).
A stratified Cox proportional-hazards model 
was used for the primary outcome analysis, with 
trial group as a fixed factor. Conditional to con-
firmation of noninferiority, superiority testing 
was performed on the primary outcome. Analyses 
of all other outcomes were not controlled for 
multiple comparisons and should be interpreted 
as exploratory. Prespecified sensitivity and sub-
group analyses explored the robustness of the 
primary outcome analysis. Secondary efficacy 
outcomes and adverse events were assessed by 
means of descriptive statistics.
R esult s
Patients
Between January and August 2017, a total of 
3183 patients were randomly assigned to oral 
semaglutide (1591 patients) or placebo (1592 pa-
tients). The median time in the trial (including 
follow-up) was 15.9 months (range, 0.4 to 20.0), 
and approximately 75% of the patients received 
oral semaglutide or placebo for more than 1 year. 
In total, 3172 patients (99.7%) completed the 
trial; 1347 (84.7%) completed the trial regimen 
with oral semaglutide and 1435 (90.1%) with 
placebo (Fig. S2 in the Supplementary Appen-
dix). Vital-status information was collected for 
the 11 patients who did not complete the trial, 
thus accounting for all patients who took part. 
Most patients (1106 of 1347, 82.1%) assigned to 
oral semaglutide who completed the trial regi-
men were receiving the 14-mg dose by the visit 
at the end of the treatment period (Fig. S3 in the 
Supplementary Appendix).
Baseline characteristics were similar in the 
two groups. Patients were predominantly male 
(2176 patients, 68.4%), and 2695 patients (84.7%) 
were 50 years of age or older and had established 
cardiovascular disease or chronic kidney disease 
(Table 1, and Tables S1 and S2 in the Supple-
mentary Appendix). At baseline, the mean (±SD) 
body weight was 90.9±21.2 kg, the mean body-
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mass index (the weight in kilograms divided 
by the square of the height in meters) 32.3±6.5, 
the mean glycated hemoglobin level 8.2±1.6% 
(66±18 mmol per mole), the mean age 66±7 years, 
and the mean duration of diabetes 14.9±8.5 years. 
The mean estimated GFR at baseline was 74±21 ml 
per minute per 1.73 m2.
At baseline, most patients were taking met-
formin (2463 patients, 77.4%) or insulin (1930 
patients, 60.6%); 1027 (32.3%) were taking sul-
fonylureas and 305 (9.6%) sodium–glucose co-
transporter 2 (SGLT2) inhibitors (Table S3 in the 
Supplementary Appendix). In addition, 2988 pa-
tients (93.9%) were taking antihypertensive medi-
cation, 2712 (85.2%) lipid-lowering medication, 
and 2527 (79.4%) antiplatelet or antithrombotic 
medication (Table S3 in the Supplementary Ap-
pendix). During the trial, more patients initiated 
or intensified glucose-lowering therapy in the 
placebo group than in the oral semaglutide group 
(Table S3 in the Supplementary Appendix), in-
cluding greater use of SGLT2 inhibitors (111 
patients [7.0%] vs. 50 [3.1%]).
Cardiovascular Outcomes
The primary outcome occurred in 61 of 1591 
patients (3.8%) receiving oral semaglutide and 
76 of 1592 (4.8%) receiving placebo. Thus, non-
inferiority was confirmed for oral semaglutide 
as compared with placebo, both added to stan-
Characteristic
Oral Semaglutide  
(N = 1591)
Placebo 
(N = 1592)
Total 
(N = 3183)
Age — yr 66±7 66±7 66±7
Female sex — no. (%) 507 (31.9) 500 (31.4) 1007 (31.6)
Body weight — kg 91.0±21.4 90.8±21.0 90.9±21.2
Body-mass index 32.3±6.6 32.3±6.4 32.3±6.5
Type 2 diabetes
Duration — yr 14.7±8.5 15.1±8.5 14.9±8.5
Glycated hemoglobin — % 8.2±1.6 8.2±1.6 8.2±1.6
Glycated hemoglobin — mmol/mol 66±17 66±18 66±18
Cardiovascular risk stratum — no. (%)
Age ≥50 yr and established CVD or chronic kidney 
disease
1350 (84.9) 1345 (84.5) 2695 (84.7)
Age ≥60 yr and cardiovascular risk factors only 241 (15.1) 247 (15.5) 488 (15.3)
Cardiovascular risk factors
Blood pressure — mm Hg
Systolic 135±18 136±18 136±18
Diastolic 76±10 76±10 76±10
LDL cholesterol
Geometric mean — mg/dl 77 79 78
Coefficient of variation — % 44.9 41.2 43.1
Current smoker — no. (%) 184 (11.6) 165 (10.4) 349 (11.0)
Estimated GFR
Mean — ml/min/1.73 m2 74±21 74±21 74±21
Distribution — no. (%)
≥90 ml/min/1.73 m2 464 (29.2) 455 (28.6) 919 (28.9)
60 to <90 ml/min/1.73 m2 686 (43.1) 703 (44.2) 1389 (43.6)
30 to <60 ml/min/1.73 m2 418 (26.3) 409 (25.7) 827 (26.0)
<30 ml/min/1.73 m2 16 (1.0) 13 (0.8) 29 (0.9)
Missing data 7 (0.4) 12 (0.8) 19 (0.6)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. To convert the values for low-
density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586. CVD denotes cardiovascular disease, 
and GFR glomerular filtration rate. Further summary baseline data are provided in Bain et al.23
Table 1. Selected Baseline Demographic and Clinical Characteristics of the Patients.*
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dard-of-care treatment, with a point estimate 
corresponding to a 21% difference in risk (haz-
ard ratio, 0.79; 95% confidence interval [CI], 
0.57 to 1.11; P<0.001 for noninferiority; P = 0.17 
for superiority) (Fig. 1 and Table 2). Sensitivity 
analyses were consistent with the primary analy-
sis (Fig. S4 in the Supplementary Appendix). The 
hazard ratio for the expanded outcome was 
similar to that for the primary outcome (with 
events in 83 of 1591 patients [5.2%] in the oral 
semaglutide group and 100 of 1592 [6.3%] in the 
placebo group; hazard ratio, 0.82; 95% CI, 0.61 
to 1.10) (Table 2, and Fig. S5 in the Supplemen-
tary Appendix), as was the composite of death 
from any cause, nonfatal myocardial infarction, 
or nonfatal stroke (with events in 69 of 1591 
patients [4.3%] and 89 of 1592 [5.6%], respec-
tively; hazard ratio, 0.77; 95% CI, 0.56 to 1.05).
Among the individual components of the pri-
mary outcome, death from cardiovascular causes 
occurred in 15 of 1591 patients (0.9%) in the 
oral semaglutide group and 30 of 1592 (1.9%) in 
the placebo group (hazard ratio, 0.49; 95% CI, 
0.27 to 0.92) (Fig. 1 and Table 2). First events of 
nonfatal myocardial infarction occurred in 37 of 
1591 patients (2.3%) and 31 of 1592 (1.9%), respec-
tively (hazard ratio, 1.18; 95% CI, 0.73 to 1.90). 
First events of nonfatal stroke occurred in 12 of 
1591 patients (0.8%) and 16 of 1592 (1.0%), respec-
tively (hazard ratio, 0.74; 95% CI, 0.35 to 1.57).
Death from any cause occurred in 23 of 1591 
patients (1.4%) in the oral semaglutide group 
and 45 of 1592 (2.8%) in the placebo group (haz-
ard ratio, 0.51; 95% CI, 0.31 to 0.84) (Table 2). 
First events of unstable angina resulting in hos-
pitalization occurred in 11 of 1591 patients 
(0.7%) and 7 of 1592 (0.4%), respectively (hazard 
ratio, 1.56; 95% CI, 0.60 to 4.01). First events of 
heart failure resulting in hospitalization occurred 
in 21 of 1591 patients (1.3%) and 24 of 1592 
(1.5%), respectively (hazard ratio, 0.86; 95% CI, 
0.48 to 1.55). Results for the primary outcome 
were consistent within subgroups (Fig. S6 in the 
Supplementary Appendix).
Efficacy Outcomes
Glycated hemoglobin levels decreased more in 
the oral semaglutide group than in the placebo 
group (mean change from baseline to end of 
trial, –1.0 vs. –0.3 percentage points), as did 
body weight (mean change from baseline to end 
of trial, –4.2 kg vs. –0.8 kg) (Fig. 2, and Fig. S7 
in the Supplementary Appendix). Systolic blood 
pressure decreased more in the oral semaglutide 
group than in the placebo group (Table S4 in 
the Supplementary Appendix), and levels of 
low-density lipoprotein cholesterol and triglyc-
erides were modestly lower in the oral sema-
glutide group (Fig. S8 in the Supplementary 
Appendix).
Adverse Events and Safety
Serious adverse events occurred in 301 of 1591 
patients (18.9%) in the oral semaglutide group 
and 358 of 1592 (22.5%) in the placebo group 
(Table 3). Serious adverse events were varied and 
involved several organ systems (Table S5 in the 
Supplementary Appendix).
More patients permanently discontinued oral 
semaglutide than placebo (184 of 1591 patients 
[11.6%] vs. 104 of 1592 [6.5%]) (Table 3, and 
Table S6 in the Supplementary Appendix). This 
difference was driven by gastrointestinal adverse 
events (in 108 of 1591 patients [6.8%] in the oral 
semaglutide group vs. in 26 of 1592 [1.6%] in 
the placebo group) (Table 3), primarily nausea 
(in 46 of 1591 patients [2.9%] vs. in 8 of 1592 
[0.5%]), vomiting (in 24 of 1591 patients [1.5%] 
vs. in 4 of 1592 [0.3%]), and diarrhea (in 22 of 
1591 patients [1.4%] vs. in 6 of 1592 [0.4%]), 
mostly nonserious. However, serious adverse 
events led to permanent discontinuation of oral 
semaglutide in 41 of 1591 patients (2.6%) and of 
placebo in 48 of 1592 patients (3.0%).
There were 68 deaths during the trial (in 23 
of 1591 patients in the oral semaglutide group 
and in 45 of 1592 in the placebo group). The 
most frequent underlying causes of death were 
cardiovascular (in 10 of 23 deaths with oral 
semaglutide and in 23 of 45 deaths with place-
bo) (Table S7 in the Supplementary Appendix). 
There was no clustering of causes among deaths 
from noncardiovascular causes.
The percentage of patients with adverse events 
related to diabetic retinopathy during the trial 
(identified through a search of terms in the Medi-
cal Dictionary for Regulatory Activities, version 20.1) 
was 7.1% (113 of 1591 patients) with oral sema-
glutide and 6.3% (101 of 1592) with placebo 
(Table S8 in the Supplementary Appendix). Most 
cases were nonproliferative and were identified 
during routine examinations (111 of 120 cases 
[92.5%] with oral semaglutide and 94 of 110 
[85.5%] with placebo); 174 of 230 cases (75.7%) 
resulted in no new treatment. In the placebo 
group, one serious retinopathy event and one 
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event leading to discontinuation of placebo were 
reported.
Despite improved glycemic control with oral 
semaglutide, the percentage of patients with se-
vere hypoglycemia was 1.4% (23 of 1591 patients), 
as compared with 0.8% (13 of 1592) with placebo. 
All severe hypoglycemic events occurred in pa-
tients receiving concomitant insulin or sulfonyl-
ureas at the time of the event.
No unexpected adverse events were reported, 
and there were no apparent imbalances in adju-
dicated adverse events between the two groups 
(Table 3, and Table S9 in the Supplementary Ap-
pendix). There was one confirmed case of acute 
pancreatitis with oral semaglutide and three cases 
with placebo. Malignant neoplasms were con-
firmed in 41 of 1591 patients (2.6%) in the oral 
semaglutide group and 48 of 1592 (3.0%) in the 
placebo group; in the oral semaglutide group, 
there was no evidence of clustering in any organ 
system. There was one case of medullary thyroid 
cancer in a patient receiving oral semaglutide 
who had preexisting thyroid nodules and an ele-
vated calcitonin level at baseline.
The mean pulse rate was increased by 4 beats 
per minute with oral semaglutide and unchanged 
with placebo (Table S4 in the Supplementary Ap-
pendix). There were no clinically relevant chang-
es in biochemical and hematologic variables.
Discussion
This cardiovascular outcomes trial met its primary 
objective of ruling out an 80% excess cardiovascu-
lar risk with oral semaglutide, confirming non-
inferiority to placebo for the primary outcome 
(hazard ratio, 0.79; 95% CI, 0.57 to 1.11). This 
finding is consistent with those of other pub-
lished cardiovascular outcomes trials of GLP-1 
receptor agonists, all of which confirmed the 
absence of excess cardiovascular risk.12-16
Significant benefits with respect to the pri-
mary outcome were observed in three cardiovas-
cular outcomes trials of GLP-1 receptor agonists 
(liraglutide in the Liraglutide Effect and Action 
in Diabetes: Evaluation of Cardiovascular Out-
come Results [LEADER] trial,14 albiglutide in the 
Harmony Outcomes trial,15 and subcutaneous 
semaglutide in SUSTAIN-616) as well as for dula-
glutide in the Researching Cardiovascular Events 
with a Weekly Incretin in Diabetes (REWIND) 
trial.17 The SUSTAIN-6 and LEADER trials were 
prespecified to be of longer duration than the 
current trial,14,16 and the Harmony Outcomes 
Outcome Oral Semaglutide (N = 1591) Placebo (N = 1592)
Hazard Ratio 
(95% CI)
no. (%) no./100 person-yr no. (%) no./100 person-yr
Primary outcome† 61 (3.8) 2.9 76 (4.8) 3.7 0.79 (0.57–1.11)‡
Expanded composite outcome§ 83 (5.2) 4.0 100 (6.3) 4.9 0.82 (0.61–1.10)
Death from any cause, nonfatal myocardial 
infarction, or nonfatal stroke
69 (4.3) 3.3 89 (5.6) 4.4 0.77 (0.56–1.05)
Death from any cause 23 (1.4) 1.1 45 (2.8) 2.2 0.51 (0.31–0.84)
Death from cardiovascular causes 15 (0.9) 0.7 30 (1.9) 1.4 0.49 (0.27–0.92)
Nonfatal myocardial infarction 37 (2.3) 1.8 31 (1.9) 1.5 1.18 (0.73–1.90)
Nonfatal stroke 12 (0.8) 0.6 16 (1.0) 0.8 0.74 (0.35–1.57)
Unstable angina resulting in hospitalization 11 (0.7) 0.5 7 (0.4) 0.3 1.56 (0.60–4.01)
Heart failure resulting in hospitalization 21 (1.3) 1.0 24 (1.5) 1.2 0.86 (0.48–1.55)
*  Outcomes are first events that were positively adjudicated by the external adjudication committee. Data are for the full analysis set during 
the in-trial observation period (from randomization to the final follow-up visit). Deaths from cardiovascular causes included deaths for 
which the cause was undetermined. CI denotes confidence interval.
†  The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
‡  P<0.001 for noninferiority, P = 0.17 for superiority. The primary outcome analysis was controlled for multiple comparisons. Confidence inter-
vals for other analyses have not been adjusted for multiple comparisons.
§  The expanded composite outcome consisted of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, unstable 
angina resulting in hospitalization, or heart failure resulting in hospitalization.
Table 2. Primary and Secondary Cardiovascular Outcomes.*
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trial was designed to randomly assign approxi-
mately three times as many patients as were en-
rolled in our trial.15 Consequently, fewer events 
were observed in our trial (in 137 of 3183 patients) 
than in SUSTAIN-6 (in 254 of 3297),16 the LEADER 
trial (in 1302 of 9340),14 or the Harmony Out-
comes trial (in 766 of 9463).15 However, the haz-
ard ratios were similar in the present trial and 
SUSTAIN-6,16 which may suggest that the car-
diovascular effect of semaglutide is independent 
of the route of administration.
Generally, the results were consistent across 
the components of the primary outcome and the 
other cardiovascular outcomes (e.g., hospitaliza-
tion for heart failure). Thus, oral semaglutide has 
a cardiovascular safety profile similar to that of the 
subcutaneous form, as shown in SUSTAIN-6.16
No treatment interactions were evident in 
Figure 2. Efficacy Outcomes (In-Trial Observation Period).
The curves show the observed change from baseline in the glycated hemoglobin level (Panel A) and body weight 
(Panel B). Data are for the full analysis set during the in-trial observation period, which was from randomization to 
the last visit (end of treatment). The end of treatment occurred when the required number of first major adverse 
cardiovascular events was exceeded. The individual patients’ in-trial observation period ranged from 2 to 87 weeks, 
with a median duration of 69 weeks. I bars indicate standard errors.
M
ea
n 
G
ly
ca
te
d 
H
em
og
lo
bi
n 
(%
)
M
ea
n 
G
ly
ca
te
d 
H
em
og
lo
bi
n
(m
m
ol
/m
ol
)
8.5
7.5
8.0
7.0
6.5
6.0
0.0
60
65
55
45
50
0
0 14 26 38 50 End of
Treatment
Period
B Body Weight
A Glycated Hemoglobin
No. at Risk
Oral semaglutide
Placebo
1581
1574
1544
1541
8
1548
1549
1528
1526
1512
1500
1271
1271
62
744
744
1497
1486
Oral semaglutide
Placebo
M
ea
n 
W
ei
gh
t (
kg
)
100
96
98
94
92
90
84
86
88
0
0 10 26 38 50 End of
Treatment
Period
Weeks since Randomization
No. at Risk
Oral semaglutide
Placebo
1590
1592
1552
1558
84
1565
1563
1578
1572
1535
1533
1518
1520
1280
1278
62
749
754
1511
1493
Oral semaglutide
Placebo
n engl j med 381;9 nejm.org August 29, 2019 849
Or al Semaglutide and Cardiovascular Outcomes in Diabetes
subgroup analyses, including in patients with 
established cardiovascular disease or chronic kid-
ney disease as compared with those with cardio-
vascular risk factors only. These data should be 
interpreted with caution owing to low patient 
numbers and wide confidence intervals.
More patients received treatment with an 
SGLT2 inhibitor after randomization in the pla-
cebo group than in the oral semaglutide group. 
These drugs have been shown to reduce cardio-
vascular risk,24-26 which could have potentially 
affected the treatment difference for the primary 
outcome. However, few patients initiated SGLT2 
inhibitors in the current trial (and they used 
these drugs over a shorter duration than in trials 
showing the aforementioned reduction in car-
diovascular risk), which makes an influence on 
the primary outcome unlikely in our view.
Oral semaglutide reduced glycated hemoglo-
bin levels and body weight in the present trial, 
which is consistent with the phase 3a efficacy 
and safety trial PIONEER 327 and with data for 
subcutaneous semaglutide in SUSTAIN-6.16 In our 
trial, oral semaglutide was associated with gly-
cemic benefits despite instructions to intensify 
glucose-lowering therapy in all patients as need-
ed and despite more patients in the placebo group 
receiving additional glucose-lowering medications.
No unexpected adverse events were identified 
with oral semaglutide. More patients permanent-
ly discontinued oral semaglutide than placebo, 
mostly due to gastrointestinal events, as observed 
with all GLP-1 receptor agonists (including sub-
cutaneous semaglutide). Fewer serious adverse 
events and deaths occurred in the oral semaglu-
tide group than in the placebo group. The differ-
ence between the two groups in the number of 
deaths was largely accounted for by deaths from 
cardiovascular causes (10 of 23 deaths in the oral 
semaglutide group vs. 23 of 45 in the placebo 
group), although there were also more deaths 
from noncardiovascular causes in the placebo 
group (8 of 23 deaths vs. 15 of 45).
In SUSTAIN-6, subcutaneous semaglutide was 
Event
Oral Semaglutide  
(N = 1591)
Placebo  
(N = 1592)
number of patients (percent)
Adverse event leading to permanent discontinuation of oral semaglutide 
or placebo
184 (11.6) 104 (6.5)
According to system organ class†
Gastrointestinal disorders 108 (6.8) 26 (1.6)
Metabolism and nutrition disorders 19 (1.2) 7 (0.4)
Nervous system disorders 17 (1.1) 13 (0.8)
Serious adverse event 301 (18.9) 358 (22.5)
Leading to permanent discontinuation of oral semaglutide or placebo 41 (2.6) 48 (3.0)
Adverse events of special interest
Acute kidney injury‡ 32 (2.0) 37 (2.3)
Acute pancreatitis‡ 1 (0.1) 3 (0.2)
Retinopathy or related complications§¶ 113 (7.1) 101 (6.3)
Severe hypoglycemia§ 23 (1.4) 13 (0.8)
Malignant neoplasms‡¶‖ 41 (2.6) 48 (3.0)
*  Adverse events were summarized descriptively for both the treatment period (from the date of the first dose to the date 
of the last dose plus 38 days or the final follow-up visit [whichever occurred first]) and the in-trial observation period 
(from randomization to the final follow-up visit). Further adverse events of special interest are shown in Table S9 in the 
Supplementary Appendix.
†  Shown are events with an incidence of at least 1% in either trial group.
‡  These events were confirmed by the event-adjudication committee.
§  These events were identified through a search of terms in the Medical Dictionary for Regulatory Activities, version 20.1.
¶  Data are for the in-trial observation period.
‖  Malignant thyroid neoplasms were excluded. Such neoplasms occurred in two patients receiving oral semaglutide: one 
patient had medullary thyroid cancer and one had a recurrence of a previous thyroid cancer.
Table 3. Adverse Events (during the Treatment Period unless Specified).*
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associated with a higher risk of diabetic retinopa-
thy complications than placebo.16 Most events 
occurred early in that trial, possibly attributable 
to the magnitude and rapidity of the reduction 
in glycated hemoglobin levels in patients with 
preexisting diabetic retinopathy.28 Given that re-
sult, patients with proliferative retinopathy or 
maculopathy resulting in active treatment were 
excluded from our trial. We observed no appar-
ent imbalance between the trial groups in adverse-
event reporting of diabetic retinopathy; almost 
all cases were nonproliferative and did not result 
in additional treatment during the trial. A long-
term trial to investigate the effects of semaglu-
tide on the development and progression of dia-
betic retinopathy is ongoing (ClinicalTrials.gov 
number, NCT03811561).
Our event-driven, double-blind trial was pow-
ered to investigate whether there was an excess 
cardiovascular risk with oral semaglutide. A high 
completion rate (99.7%), a high percentage of pa-
tients who continued to receive oral semaglutide 
(>80%), and full vital status known at trial end for 
all randomly assigned patients indicate high valid-
ity for the conduct of the trial and the results.
In conclusion, the present trial showed non-
inferiority of oral semaglutide to placebo (haz-
ard ratio, 0.79; 95% CI, 0.57 to 1.11), ruling out 
an 80% excess cardiovascular risk. Gastrointes-
tinal adverse events were the major reason for 
discontinuation of oral semaglutide.
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